Dual Nucleoside Analogue Therapy for Feline Infectious Peritonitis: Veterinary Evidence and Clinical Guidance
- BasmiFIP Philippines
- Mar 26
- 3 min read
Published clinical evidence and pharmacological rationale supporting combined GS-441524 and EIDD-1931 therapy for Feline Infectious Peritonitis (FIP) in cats.
Clinical Background
Feline Infectious Peritonitis (FIP), resulting from virulent biotypes of feline coronavirus (FCoV), became treatable with the introduction of GS-441524 in 2019. Standard monotherapy protocols (4-10 mg/kg, 84 days) achieve high remission rates across all presentations. However, single-agent therapy carries limitations including resistance potential during prolonged treatment, limited CNS penetration in neurological cases, and incomplete viral clearance in some patients.
CURE FIP™ Dual Antiviral Oral Capsules combine GS-441524 (chain terminator) and EIDD-1931 (lethal mutagen) to address these limitations through complementary mechanism targeting.
Dual Mechanism Rationale
GS-441524 (Chain Termination): Adenosine nucleoside analogue. Phosphorylated intracellularly to GS-443902 (active triphosphate). Acts as substrate for viral RdRp. 1'-cyano substitution causes steric clash upon incorporation, terminating RNA chain elongation. Non-cytotoxic at 100x effective dose in CRFK cells. Plasma half-life ~24 hours supports q24h dosing (Murphy et al., Vet Microbiol, 2018).
EIDD-1931 (Lethal Mutagenesis): Active metabolite of molnupiravir (EIDD-2801). Mutagenic ribonucleoside that incorporates into viral RNA without immediate chain termination. Induces C-to-U and G-to-A transition mutations at increasing frequency across successive replication rounds until cumulative mutation burden exceeds error threshold, causing viral population collapse. Feline PK: Cmax ~1,551 ng/mL (~6 μM), detectable 12h post-dose, supporting q12h dosing (Pathogens, 2025).
Combined: Chain termination reduces viral RNA output. Lethal mutagenesis degrades fidelity of remaining copies. Together: higher genetic barrier to resistance requiring simultaneous escape from orthogonal mechanisms.
Published Evidence Base
GS-441524 Monotherapy
Pedersen et al. (2019): UC Davis field trial. 31 cats, naturally occurring Feline Infectious Peritonitis (FIP) (26 effusive, 5 non-effusive). GS-441524 2.0-4.0 mg/kg SC q24h, min. 12 weeks. 24/26 completers in sustained remission. Fever resolution 12-36h. Effusion resolution 10-14d. J Feline Med Surg, 21(4):271-281
Coggins et al. (2023): 307 cats, legally sourced remdesivir/GS-441524 (Australia, UK). Three protocols: RDV alone (33.9%), RDV then GS (55.7%), GS alone (10.4%). 84.4% alive at longest follow-up (median 248d). Relapse rate 10.8%. Complete response within 30d predicted significantly better survival. J Vet Intern Med
Krentz et al. (2024): Prospective RCT, LMU Munich. 40 cats, effusive Feline Infectious Peritonitis (FIP). 15 mg/kg PO q24h. 42 vs 84 days. 38/40 recovered with rapid clinical/laboratory improvement and significant viral RNA load reduction. No difference between durations. Pathogens
Delaplace et al. (2025): PRISMA systematic review. 11 studies, 650 cases. Overall success 84.6% (550/650). Higher with combination therapy, lower in effusive (OR ~0.49 vs non-effusive) and neurological cases. Neuro combination outcomes: GS+RDV 10/10 survived, GS+GC376 7/8 survived. Pathogens
Molnupiravir/EIDD-1931
Kanai et al. (2023): First published series. 18 cats, MPV 10-20 mg/kg PO q12h, 84d. 4 effusive cats died within 7d. 14/14 completers in remission (139-206d follow-up). Transient ALT elevations in 3 cats. J Vet Intern Med
Kanai et al. (2024): 118 cats (76 effusive). 59 GS vs 59 MPV. Mortality: 20.3% GS, 13.6% MPV (p=0.326). Remission among completers: GS 48/48, MPV 51/52. Comparable adverse events. Front Vet Sci
Roy et al. (2022): Ohio State rescue therapy. 26 cats post-GS failure. 24/26 disease-free. AEs only >23 mg/kg q12h. Pathogens
Combination Therapy Evidence
Li et al. (2022): 46 cats, GS+GC376, 4 weeks. 45/46 (97.8%) survived, 43 clinically normal at treatment end, 2 required extended GS monotherapy. All 45 relapse-free at 10 months. Front Vet Sci
Clinical Considerations
Neurological Feline Infectious Peritonitis (FIP)
Most challenging presentation. CSF penetration of GS-441524: 7-21% of plasma levels with inter-individual variability. The 2025 systematic review demonstrated that combination therapy significantly improved neurological outcomes compared to monotherapy. EIDD-1931 provides supplementary antiviral pressure compensating for suboptimal CNS penetration.
Resistance Prevention
GS-441524 resistance during prolonged monotherapy is documented. The 84-day treatment creates sustained selective pressure. Dual mechanisms substantially raise the genetic barrier by requiring simultaneous escape mutations against both chain termination and lethal mutagenesis.
Incomplete Remission and Relapse
Approximately 10-11% relapse rate observed in published GS-441524 studies. Dual antiviral therapy may reduce residual viral reservoirs more effectively, lowering relapse risk. EIDD-1931 has demonstrated efficacy as rescue agent for GS-refractory cases, suggesting complementary antiviral coverage.
Monitoring
Standard GS-441524 monitoring protocols apply. Key parameters: CBC (neutrophil count, given potential EIDD-1931 neutropenia at higher doses), serum biochemistry (ALT activity), body weight, clinical signs at regular intervals. Liver support supplementation advisable throughout treatment. Post-treatment observation minimum 12 weeks.
Summary
The GS-441524 and EIDD-1931 combination represents a pharmacologically rational advancement in Feline Infectious Peritonitis (FIP) therapy. Orthogonal mechanism targeting (chain termination + lethal mutagenesis) provides enhanced viral suppression, a higher genetic barrier to resistance, and potentially improved outcomes in complex presentations. The existing individual and combination therapy evidence base provides a compelling rationale for dual nucleoside analogue therapy.
Treatment protocols and clinical consultation: basmifipphilippines.com | WhatsApp support available.
Comments